Diabetic Gastroparesis Pipeline Review H1 2019: Therapeutic Assessment of 8 Companies & 10 Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetic
Gastroparesis – Pipeline Review, H1 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.

Diabetic Gastroparesis – Pipeline Review, H1 2019, provides an overview
of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

This latest pipeline guide Diabetic Gastroparesis – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Diabetic Gastroparesis (Gastrointestinal), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also
reviews of key players involved in therapeutic development for Diabetic
Gastroparesis and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Pre-Registration,
Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 1
respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Diabetic Gastroparesis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Diabetic
  Gastroparesis (Gastrointestinal) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Diabetic
  Gastroparesis (Gastrointestinal) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Key Topics Covered:

Diabetic Gastroparesis – Overview

Diabetic Gastroparesis – Therapeutics Development

• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies

Diabetic Gastroparesis – Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Diabetic Gastroparesis – Companies Involved in Therapeutics Development

• AlfaSigma SpA
• Allergan Plc
• Censa Pharmaceuticals Inc
• ETX Pharma Inc
• Evoke Pharma Inc
• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• Vanda Pharmaceuticals Inc

Diabetic Gastroparesis – Drug Profiles

• CNSA-001 – Drug Profile
• ETX-101 – Drug Profile
• ETX-301 – Drug Profile
• metoclopramide – Drug Profile
• prucalopride succinate – Drug Profile
• relamorelin – Drug Profile
• renzapride – Drug Profile
• TAK-906 – Drug Profile
• tradipitant – Drug Profile
• velusetrag – Drug Profile

Featured News & Press Releases

Jan 07, 2019: Evoke Pharma signs commercial and financial agreement for
its Lead Product Gimoti in the U.S. with Novos Growth Partners

Dec 03, 2018: Vanda announces positive phase II study results for
Tradipitant in patients with gastroparesis

Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018

Aug 16, 2018: Evoke Pharma’s Gimoti NDA Accepted for FDA Review

Jun 04, 2018: Evoke Announces FDA Submission of New Drug Application for
Gimoti

May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for
Renzapride in Patients with Gastroparesis

May 10, 2018: Evoke Granted Gender Specific Patent for Gimoti in Mexico

Apr 30, 2018: Evoke Granted First Gender Specific Patent for Gimoti

Feb 15, 2018: Evoke Announces Discovery of Sex-Based Pharmacokinetic
Differences for Gimoti

Oct 27, 2017: Evoke Pharma Announces Conference Call to Review the
Successful Results of Comparative Exposure Pharmacokinetic Study for
Gimoti

Oct 23, 2017: Evoke Pharma Announces Positive Topline Results from
Comparative Exposure Pharmacokinetic Study for Gimoti

Oct 04, 2017: Evoke Pharma to Participate in the Oppenheimer & Co.
Specialty Pharmaceuticals Conference

Sep 12, 2017: Evoke Pharma Completes Dosing for Gimoti Comparative
Exposure Pharmacokinetic Study

Sep 05, 2017: Evoke Pharma to Present at the 19th Annual Rodman &
Renshaw Global Investment Conference

Aug 14, 2017: Evoke Pharma Initiates Comparative Exposure
Pharmacokinetic Study for Gimoti

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/63h3j3/diabetic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs , Endocrine
and Metabolic Disorders Drugs